Structures by: Vega D. R.
Total: 21
Bendamustine Hydrochloride Monohydrate
C16H22Cl2N3O2,Cl,H2O
Acta Crystallographica Section B (2019) 75, 6
a=4.6490(6)Å b=47.213(5)Å c=8.9051(10)Å
α=90° β=96.222(7)° γ=90°
Bendamustine Hydrochloride
C16H22Cl2N3O2,Cl
Acta Crystallographica Section B (2019) 75, 6
a=4.722(4)Å b=45.671(19)Å c=8.798(7)Å
α=90° β=97.66(6)° γ=90°
Bendamustine Hydrochloride
C16H22Cl2N3O2,Cl
Acta Crystallographica Section B (2019) 75, 6
a=23.0502(6)Å b=6.7836(2)Å c=25.4596(7)Å
α=90° β=114.2620(10)° γ=90°
Pridinol mesylate
C20H26NO,CH3O3S
Acta Crystallographica Section B (2018) 74, 3 304-310
a=8.7198(2)Å b=20.996(8)Å c=10.9186(3)Å
α=90° β=94.357(2)° γ=90°
Pridinol mesylate hydrate
C20H26NO,CH3O3S,H2O
Acta Crystallographica Section B (2018) 74, 3 304-310
a=8.2086(2)Å b=17.9355(6)Å c=15.0983(5)Å
α=90° β=94.770(2)° γ=90°
Tapentadol
C14H24NO,Cl
Acta Crystallographica Section B (2019) 75, 2
a=7.1062(2)Å b=11.5821(3)Å c=17.3894(5)Å
α=90° β=94.9978(11)° γ=90°
Tapentadol
C14H24NO,Cl
Acta Crystallographica Section B (2019) 75, 2
a=7.0653(2)Å b=11.8351(3)Å c=17.6593(5)Å
α=90° β=90° γ=90°
Tapentadol
C14H24NO,Cl
Acta Crystallographica Section B (2019) 75, 2
a=7.1350(2)Å b=11.6402(4)Å c=17.4546(5)Å
α=90° β=94.7791(14)° γ=90°
13-Chloro-2-(2-chlorophenyl)-3-oxa-6,9-diazatricyclo[8.4.0.0^2,6^]tetradeca-1(10),11,13-trien-8-one
C17H14Cl2N2O2
Acta crystallographica. Section C, Structural chemistry (2019) 75, Pt 7 851-858
a=16.7989(6)Å b=17.0054(7)Å c=22.1341(7)Å
α=78.897(2)° β=100.411(4)° γ=90.042(3)°
C22H18O
C22H18O
Acta Crystallographica Section E (2006) 62, 4 o1618-o1620
a=9.0850(10)Å b=5.9810(10)Å c=30.091(6)Å
α=90° β=95.66(3)° γ=90°
Alprozolam dihydrate
C17H17ClN4O2
Acta Crystallographica Section C (1999) 55, 12 2094-2096
a=8.5705(17)Å b=13.657(3)Å c=14.895(3)Å
α=84.26(3)° β=81.95(3)° γ=87.11(3)°
Poly[[μ~2~-aqua[μ~3~-1-hydroxy-2-(1<i>H</i>,3<i>H</i>-imidazol-3-ium-1- yl)ethylidenediphosphonato]potassium(I)] monohydrate]
C5H11KN2O8P2,H2O
Acta Crystallographica Section C (2010) 66, 1 m13-m16
a=6.9610(14)Å b=7.0380(14)Å c=13.322(3)Å
α=94.82(2)° β=103.75(3)° γ=92.58(2)°
Sodium zoledronate
C20H45N8Na3O32P8,2(H2O)
Acta Crystallographica Section C (2010) 66, 4 m122-m126
a=9.0690(18)Å b=11.309(2)Å c=12.594(3)Å
α=115.58(3)° β=98.86(3)° γ=99.76(3)°
Diaquabis[dihydrogen 1-hydroxy-2-(imidazol-3-ium-1-yl)ethylidene-1,1-diphosphonato- κ^2^<i>O</i>,<i>O</i>]magnesium(II)
C10H22MgN4O16P4
Acta Crystallographica Section C (2010) 66, 6 m166-m170
a=7.4680(15)Å b=8.4390(17)Å c=9.819(2)Å
α=105.11(3)° β=111.98(3)° γ=97.04(3)°
<i>catena</i>-Poly[[aquacalcium(II)]-μ~3~-[hydrogen 1-hydroxy-2-(imidazol-3-ium-1-yl)ethylidene-1,1-diphosphonato]- κ^5^<i>O</i>:<i>O</i>,<i>O</i>:<i>O</i>',<i>O</i>'']
C5H10CaN2O8P2
Acta Crystallographica Section C (2010) 66, 6 m166-m170
a=13.7027(15)Å b=7.0429(8)Å c=11.0040(12)Å
α=90.00° β=94.007(10)° γ=90.00°
1,c-3-diphenyltetran-r-1-ol
C22H20O
Acta Crystallographica Section C (2009) 65, 2 o35-o38
a=16.546(3)Å b=13.124(3)Å c=31.942(6)Å
α=90° β=100.62(3)° γ=90°
Diaquabis[1-hydroxy-2-(imidazol-3-ium-1-yl)-1,1-ethylidenediphophonato- κ^2^<i>O</i>,<i>O</i>']zinc(II)
C10H22N4O16P4Zn
Acta Crystallographica Section E (2009) 65, 11 m1428-m1429
a=7.4570(10)Å b=8.408(2)Å c=9.843(2)Å
α=105.06(3)° β=112.23(3)° γ=97.05(3)°
Aquabis[1-hydroxy-2-(imidazol-3-ium-1-yl)-1,1-ethylidenediphophonato- κ^2^<i>O</i>,<i>O</i>')zinc(II)) dihydrate
C10H20N4O15P4Zn,2(H2O)
Acta Crystallographica Section E (2009) 65, 11 m1430-m1431
a=12.089(2)Å b=9.858(2)Å c=18.831(4)Å
α=90.00° β=95.09(3)° γ=90.00°
[2-(1-Hydroxycyclohexyl)-2-(4-methoxyphenyl)ethyl]dimethylazanium benzenesulfonate monohydrate
C17H28NO2,C6H5O3S,H2O
Acta Crystallographica Section E (2013) 69, 12 o1737-o1738
a=10.1163(5)Å b=10.2176(4)Å c=13.8162(6)Å
α=72.074(4)° β=70.108(4)° γ=63.889(5)°
C28H40N2O5
C28H40N2O5
The Journal of organic chemistry (2016) 81, 10 4179-4189
a=33.30(10)Å b=5.412(5)Å c=15.00(3)Å
α=90° β=91.1(5)° γ=90°
C26H37NO5
C26H37NO5
The Journal of organic chemistry (2016) 81, 10 4179-4189
a=5.5207(6)Å b=12.9380(12)Å c=17.1775(13)Å
α=94.761(7)° β=93.119(7)° γ=97.721(8)°